Answers are grounded in this paper and cite their sources.
Background/Objectives: Acetylcholinesterase inhibitors (AChEIs) are the standard symptomatic treatment for Alzheimer’s dementia, and the German S3 guideline recommends choosing between donepezil, rivastigmine and galantamine on the basis of their adverse effect and interaction profiles. Comparative data on the course of dementia in primary care are lacking. Methods: This retrospective active-comparator new-user cohort study used the IQVIA Disease Analyzer database (German general practices, 2011–2024). Patients aged ≥65 years with newly documented dementia who initiated donepezil were compared with patients who initiated rivastigmine or galantamine. The primary outcome was a composite of six clinically selected proxy variables of dementia progression: mood-related symptoms, faecal incontinence, dehydration, first prescription of an antipsychotic or of memantine, and nursing home admission. Cox regression with overlap weighting, absolute risk differences and multiple sensitivity analyses were applied. Results: Of 95,327 patients with newly documented dementia, 7.8% received a first AChEI prescription in general practice within two years; prescriptions by specialists were not captured. The study cohort comprised 6248 patients (donepezil 3536; rivastigmine/galantamine 2712). The outcome occurred in 46.3% and 45.0% of patients, respectively. Donepezil was not associated with a different risk of proxy-defined progression (hazard ratio [HR] 0.97; 95% confidence interval [CI] 0.89–1.04); the difference in weighted cumulative incidence was −1.9 percentage points (95% CI −4.3 to 0.2) after one year and 0.5 percentage points (−3.9 to 4.4) after five years. The result was consistent across all confounder-adjustment methods, outcome definitions and subgroups, in on-treatment and competing-risk analyses, and in separate comparisons with rivastigmine (HR 0.94; 0.86–1.02) and galantamine (HR 1.02; 0.90–1.16), although the main comparison group combined two agents with different pharmacological profiles. End of documentation, a proxy for death or loss to follow-up, occurred in 30.4% and 33.1%; competing-risk and scenario analyses yielded consistent results. Nursing home admission was less frequent with donepezil (HR 0.84; 0.73–0.97), but this difference was not significant after correction for multiple testing or among patients with Alzheimer’s disease. Conclusions: In patients aged ≥65 years who initiated an AChEI in German general practices, no detectable difference in proxy-defined dementia progression was observed between donepezil and rivastigmine or galantamine. This study does not demonstrate definitive equivalence and cannot prove that the drugs are therapeutically interchangeable. The findings indicate that, in this population and within these limitations, no detectable difference was observed in the measured outcomes. The lower risk of nursing home admission with donepezil is hypothesis-generating only. The low proportion of AChEI prescriptions in general practice, which excludes specialist prescribing, is notable; as only active treatments were compared, the study does not show whether AChEI treatment is beneficial compared with no treatment.
No takes yet. Share an insight, caveat, or question.
Bohlken et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: